Buccal Drug Delivery Systems Market Size, Share & Trends Analysis Report
| 出版社 | Grand View Research |
| 出版年月 | 2024年7月 |
| ページ数 | 120 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 5,950 |
| 種別 | 英文調査報告書 |
Buccal Drug Delivery Systems Market Growth & Trends
The global buccal drug delivery systems market size is expected to reach USD 6.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
世界の口腔内ドラッグデリバリーシステム市場規模は、2030 年までに 65 億 6,000 万米ドルに達すると予想されています。市場は 2024 年から 2030 年にかけて 6.2% の CAGR で成長すると予想されています。
Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.
Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the Covid-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.
Buccal Drug Delivery Systems Market Report Scope
| Report Attribute | Details |
| Market size value in 2024 | USD 4.56 billion |
| Revenue forecast in 2030 | USD 6.56 billion |
| Growth rate | CAGR of 6.2% from 2024 to 2030 |
| Base year for estimation | 2023 |
| Historical data | 2018 – 2022 |
| Forecast period | 2024 – 2030 |
| Quantitative units | Revenue in USD million/billion and CAGR from 2024 to 2030 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | Type, application, end-use, region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
| Key companies profiled | Teva Pharmaceutical Industries Ltd.; GSK plc; Pfizer Inc.; Generex Biotechnology Corporation (LUMITOS AG); ARx, LLC.; Catalent, Inc.; Collegium Pharmaceutical; Cynapsus Therapeutics Inc.; Endo, Inc.; Indivior PLC. |
Buccal Drug Delivery Systems Market Report Highlights
- The buccal tablets and lozenges type segment accounted for the largest revenue share in 2023 due to its wider acceptance among patients
- The smoking cessation application segment held the largest share in 2023. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
- The hospital end-user segment captured the largest revenue share in 2023 owing to a large number of admissions of geriatric patients and abundant medication supplies
- North America held the largest revenue share in 2023 due to a large number of leading manufacturers and growing research in the region
Table of Contents
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Buccal Drug Delivery Systems Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Buccal Drug Delivery Systems Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Buccal Drug Delivery Systems Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Buccal Drug Delivery Systems Market: Solution Movement Analysis, 2023 & 2030 (USD Million)
4.3. Sublingual Films
4.3.1. Sublingual Films And Wafers Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
4.4. Buccal Tablets/Lozenges
4.4.1. Buccal Tablets/Lozenges Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
4.5. Oral Sprays
4.5.1. Oral Sprays Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 5. Buccal Drug Delivery Systems Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Buccal Drug Delivery Systems Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
5.3. Pain Management
5.3.1. Pain Management Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
5.4. Smoking Cessation
5.4.1. Smoking Cessation Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
5.5. Angina Pectoris
5.5.1. Angina Pectoris Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
5.6. Others
5.6.1. Others Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 6. Buccal Drug Delivery Systems Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Buccal Drug Delivery Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospitals
6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.4. Ambulatory Centers
6.4.1. Ambulatory Centers Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
6.5. Others (Clinics, Home Health/OTC)
6.5.1. Others (Clinics, Home Health/OTC) Market Revenue Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 7. Buccal Drug Delivery Systems Market: Regional Estimates & Trend Analysis
7.1. Buccal Drug Delivery Systems Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. France Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.2. China
7.4.2.1. China Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. India Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.6. South Korea
7.4.6.1. South Korea Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Teva Pharmaceutical Industries Ltd.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/Strategic Initiatives
8.4.2. GSK plc
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/Strategic Initiatives
8.4.3. Pfizer Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/Strategic Initiatives
8.4.4. Generex Biotechnology Corporation (LUMITOS AG)
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/Strategic Initiatives
8.4.5. ARx, LLC.
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/Strategic Initiatives
8.4.6. Catalent, Inc
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/Strategic Initiatives
8.4.7. Collegium Pharmaceutical
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/Strategic Initiatives
8.4.8. Cynapsus Therapeutics Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/Strategic Initiatives
8.4.9. Endo, Inc.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/Strategic Initiatives
8.4.10. Indivior PLC
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/Strategic Initiatives